APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Neuroendocrine Tumors (NETs) Treatment

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Neuroendocrine Tumors (NETs) Treatment Market Analysis and Forecast 2026-2032

Report ID 174016490222 December 2025190 pages

Choose your research edition.

Industry ResearchNeuroendocrine Tumors (NETs) Treatment Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Neuroendocrine Tumors (NETs) Treatment Industry Growth and Trends Forecast to 203293 pages · $3,450 USDMarket StructureGlobal Neuroendocrine Tumors (NETs) Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032183 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neuroendocrine Tumors (NETs) Treatment Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Neuroendocrine Tumors (NETs) Treatment Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Neuroendocrine Tumors (NETs) Treatment market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Neuroendocrine Tumors (NETs) Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Neuroendocrine Tumors (NETs) Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Neuroendocrine Tumors (NETs) Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Neuroendocrine Tumors (NETs) Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Neuroendocrine Tumors (NETs) Treatment include Novartis AG, Pfizer, Inc, Progenics Pharmaceuticals, IpsenPharma, Hutchison MediPharma Limited, Boehringer Ingelheim International, AVEO Oncology and Advanced Accelerator Applications, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Neuroendocrine Tumors (NETs) Treatment, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Neuroendocrine Tumors (NETs) Treatment, also provides the sales of main regions and countries. Of the upcoming market potential for Neuroendocrine Tumors (NETs) Treatment, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Neuroendocrine Tumors (NETs) Treatment sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Neuroendocrine Tumors (NETs) Treatment market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Neuroendocrine Tumors (NETs) Treatment sales, projected growth trends, production technology, application and end-user industry.

Neuroendocrine Tumors (NETs) Treatment Segment by Company

Novartis AG

Pfizer, Inc

Progenics Pharmaceuticals

IpsenPharma

Hutchison MediPharma Limited

Boehringer Ingelheim International

AVEO Oncology

Advanced Accelerator Applications

Neuroendocrine Tumors (NETs) Treatment Segment by Type

Somatostatin Analogs (SSAs)

Targeted Therapy

Other

Neuroendocrine Tumors (NETs) Treatment Segment by Application

Hospitals

Clinics

Other

Neuroendocrine Tumors (NETs) Treatment Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neuroendocrine Tumors (NETs) Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neuroendocrine Tumors (NETs) Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neuroendocrine Tumors (NETs) Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Neuroendocrine Tumors (NETs) Treatment in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Neuroendocrine Tumors (NETs) Treatment manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Neuroendocrine Tumors (NETs) Treatment sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Neuroendocrine Tumors (NETs) Treatment Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Somatostatin Analogs (SSAs) Major Manufacturers Table 3. Targeted Therapy Major Manufacturers Table 4. Other Major Manufacturers Table 5. Global Neuroendocrine Tumors (NETs) Treatment Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Hospitals Major Manufacturers Table 7. Clinics Major Manufacturers Table 8. Other Major Manufacturers Table 9. Neuroendocrine Tumors (NETs) Treatment Industry Trends Table 10. Neuroendocrine Tumors (NETs) Treatment Industry Drivers Table 11. Neuroendocrine Tumors (NETs) Treatment Industry Opportunities and Challenges Table 12. Neuroendocrine Tumors (NETs) Treatment Industry Restraints Table 13. Global Neuroendocrine Tumors (NETs) Treatment Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 14. Global Neuroendocrine Tumors (NETs) Treatment Revenue by Region (2021-2026) & (US$ Million) Table 15. Global Neuroendocrine Tumors (NETs) Treatment Revenue by Region (2027-2032) & (US$ Million) Table 16. Global Neuroendocrine Tumors (NETs) Treatment Revenue Market Share by Region (2021-2026) Table 17. Global Neuroendocrine Tumors (NETs) Treatment Revenue Market Share by Region (2027-2032) Table 18. Global Neuroendocrine Tumors (NETs) Treatment Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (k units) Table 19. Global Neuroendocrine Tumors (NETs) Treatment Sales by Region (2021-2026) & (k units) Table 20. Global Neuroendocrine Tumors (NETs) Treatment Sales by Region (2027-2032) & (k units) Table 21. Global Neuroendocrine Tumors (NETs) Treatment Sales Market Share by Region (2021-2026) Table 22. Global Neuroendocrine Tumors (NETs) Treatment Sales Market Share by Region (2027-2032) Table 23. Global Neuroendocrine Tumors (NETs) Treatment Revenue by Manufacturers (US$ Million) & (2021-2026) Table 24. Global Neuroendocrine Tumors (NETs) Treatment Revenue Market Share by Manufacturers (2021-2026) Table 25. Global Neuroendocrine Tumors (NETs) Treatment Sales by Manufacturers (US$ Million) & (2021-2026) Table 26. Global Neuroendocrine Tumors (NETs) Treatment Sales Market Share by Manufacturers (2021-2026) Table 27. Global Neuroendocrine Tumors (NETs) Treatment Sales Price (US$/unit) of Manufacturers (2021-2026) Table 28. Global Neuroendocrine Tumors (NETs) Treatment Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 29. Global Neuroendocrine Tumors (NETs) Treatment Key Manufacturers Manufacturing Sites & Headquarters Table 30. Global Neuroendocrine Tumors (NETs) Treatment Manufacturers, Product Type & Application Table 31. Global Neuroendocrine Tumors (NETs) Treatment Manufacturers' Establishment Date Table 32. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 33. Global Neuroendocrine Tumors (NETs) Treatment by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 34. Global Neuroendocrine Tumors (NETs) Treatment Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Neuroendocrine Tumors (NETs) Treatment Revenue by Type (2021-2026) & (US$ Million) Table 36. Global Neuroendocrine Tumors (NETs) Treatment Revenue by Type (2027-2032) & (US$ Million) Table 37. Global Neuroendocrine Tumors (NETs) Treatment Revenue Market Share by Type (2021-2026) Table 38. Global Neuroendocrine Tumors (NETs) Treatment Revenue Market Share by Type (2027-2032) Table 39. Global Neuroendocrine Tumors (NETs) Treatment Sales by Type 2021 VS 2025 VS 2032 (k units) Table 40. Global Neuroendocrine Tumors (NETs) Treatment Sales by Type (2021-2026) & (k units) Table 41. Global Neuroendocrine Tumors (NETs) Treatment Sales by Type (2027-2032) & (k units) Table 42. Global Neuroendocrine Tumors (NETs) Treatment Sales Market Share by Type (2021-2026) Table 43. Global Neuroendocrine Tumors (NETs) Treatment Sales Market Share by Type (2027-2032) Table 44. Global Neuroendocrine Tumors (NETs) Treatment Price by Type (2021-2026) & (US$/unit) Table 45. Global Neuroendocrine Tumors (NETs) Treatment Price by Type (2027-2032) & (US$/unit) Table 46. Global Neuroendocrine Tumors (NETs) Treatment Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Neuroendocrine Tumors (NETs) Treatment Revenue by Application (2021-2026) & (US$ Million) Table 48. Global Neuroendocrine Tumors (NETs) Treatment Revenue by Application (2027-2032) & (US$ Million) Table 49. Global Neuroendocrine Tumors (NETs) Treatment Revenue Market Share by Application (2021-2026) Table 50. Global Neuroendocrine Tumors (NETs) Treatment Revenue Market Share by Application (2027-2032) Table 51. Global Neuroendocrine Tumors (NETs) Treatment Sales by Application 2021 VS 2025 VS 2032 (k units) Table 52. Global Neuroendocrine Tumors (NETs) Treatment Sales by Application (2021-2026) & (k units) Table 53. Global Neuroendocrine Tumors (NETs) Treatment Sales by Application (2027-2032) & (k units) Table 54. Global Neuroendocrine Tumors (NETs) Treatment Sales Market Share by Application (2021-2026) Table 55. Global Neuroendocrine Tumors (NETs) Treatment Sales Market Share by Application (2027-2032) Table 56. Global Neuroendocrine Tumors (NETs) Treatment Price by Application (2021-2026) & (US$/unit) Table 57. Global Neuroendocrine Tumors (NETs) Treatment Price by Application (2027-2032) & (US$/unit) Table 58. Novartis AG Company Information Table 59. Novartis AG Business Overview Table 60. Novartis AG Neuroendocrine Tumors (NETs) Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 61. Novartis AG Neuroendocrine Tumors (NETs) Treatment Product Portfolio Table 62. Novartis AG Recent Development Table 63. Pfizer, Inc Company Information Table 64. Pfizer, Inc Business Overview Table 65. Pfizer, Inc Neuroendocrine Tumors (NETs) Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 66. Pfizer, Inc Neuroendocrine Tumors (NETs) Treatment Product Portfolio Table 67. Pfizer, Inc Recent Development Table 68. Progenics Pharmaceuticals Company Information Table 69. Progenics Pharmaceuticals Business Overview Table 70. Progenics Pharmaceuticals Neuroendocrine Tumors (NETs) Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 71. Progenics Pharmaceuticals Neuroendocrine Tumors (NETs) Treatment Product Portfolio Table 72. Progenics Pharmaceuticals Recent Development Table 73. IpsenPharma Company Information Table 74. IpsenPharma Business Overview Table 75. IpsenPharma Neuroendocrine Tumors (NETs) Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. IpsenPharma Neuroendocrine Tumors (NETs) Treatment Product Portfolio Table 77. IpsenPharma Recent Development Table 78. Hutchison MediPharma Limited Company Information Table 79. Hutchison MediPharma Limited Business Overview Table 80. Hutchison MediPharma Limited Neuroendocrine Tumors (NETs) Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 81. Hutchison MediPharma Limited Neuroendocrine Tumors (NETs) Treatment Product Portfolio Table 82. Hutchison MediPharma Limited Recent Development Table 83. Boehringer Ingelheim International Company Information Table 84. Boehringer Ingelheim International Business Overview Table 85. Boehringer Ingelheim International Neuroendocrine Tumors (NETs) Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 86. Boehringer Ingelheim International Neuroendocrine Tumors (NETs) Treatment Product Portfolio Table 87. Boehringer Ingelheim International Recent Development Table 88. AVEO Oncology Company Information Table 89. AVEO Oncology Business Overview Table 90. AVEO Oncology Neuroendocrine Tumors (NETs) Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. AVEO Oncology Neuroendocrine Tumors (NETs) Treatment Product Portfolio Table 92. AVEO Oncology Recent Development Table 93. Advanced Accelerator Applications Company Information Table 94. Advanced Accelerator Applications Business Overview Table 95. Advanced Accelerator Applications Neuroendocrine Tumors (NETs) Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 96. Advanced Accelerator Applications Neuroendocrine Tumors (NETs) Treatment Product Portfolio Table 97. Advanced Accelerator Applications Recent Development Table 98. North America Neuroendocrine Tumors (NETs) Treatment Revenue by Type (2021-2026) & (US$ Million) Table 99. North America Neuroendocrine Tumors (NETs) Treatment Revenue by Type (2027-2032) & (US$ Million) Table 100. North America Neuroendocrine Tumors (NETs) Treatment Sales by Type (2021-2026) & (k units) Table 101. North America Neuroendocrine Tumors (NETs) Treatment Sales by Type (2027-2032) & (k units) Table 102. North America Neuroendocrine Tumors (NETs) Treatment Sales Price by Type (2021-2026) & (US$/unit) Table 103. North America Neuroendocrine Tumors (NETs) Treatment Sales Price by Type (2027-2032) & (US$/unit) Table 104. North America Neuroendocrine Tumors (NETs) Treatment Revenue by Application (2021-2026) & (US$ Million) Table 105. North America Neuroendocrine Tumors (NETs) Treatment Revenue by Application (2027-2032) & (US$ Million) Table 106. North America Neuroendocrine Tumors (NETs) Treatment Sales by Application (2021-2026) & (k units) Table 107. North America Neuroendocrine Tumors (NETs) Treatment Sales by Application (2027-2032) & (k units) Table 108. North America Neuroendocrine Tumors (NETs) Treatment Sales Price by Application (2021-2026) & (US$/unit) Table 109. North America Neuroendocrine Tumors (NETs) Treatment Sales Price by Application (2027-2032) & (US$/unit) Table 110. North America Neuroendocrine Tumors (NETs) Treatment Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 111. North America Neuroendocrine Tumors (NETs) Treatment Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 112. North America Neuroendocrine Tumors (NETs) Treatment Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 113. North America Neuroendocrine Tumors (NETs) Treatment Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 114. North America Neuroendocrine Tumors (NETs) Treatment Sales by Country (2021-2026) & (k units) Table 115. North America Neuroendocrine Tumors (NETs) Treatment Sales by Country (2027-2032) & (k units) Table 116. North America Neuroendocrine Tumors (NETs) Treatment Sales Price by Country (2021-2026) & (US$/unit) Table 117. North America Neuroendocrine Tumors (NETs) Treatment Sales Price by Country (2027-2032) & (US$/unit) Table 118. United States Neuroendocrine Tumors (NETs) Treatment Revenue (2021-2032) & (US$ Million) Table 119. Canada Neuroendocrine Tumors (NETs) Treatment Revenue (2021-2032) & (US$ Million) Table 120. Mexico Neuroendocrine Tumors (NETs) Treatment Revenue (2021-2032) & (US$ Million) Table 121. Europe Neuroendocrine Tumors (NETs) Treatment Revenue by Type (2021-2026) & (US$ Million) Table 122. Europe Neuroendocrine Tumors (NETs) Treatment Revenue by Type (2027-2032) & (US$ Million) Table 123. Europe Neuroendocrine Tumors (NETs) Treatment Sales by Type (2021-2026) & (k units) Table 124. Europe Neuroendocrine Tumors (NETs) Treatment Sales by Type (2027-2032) & (k units) Table 125. Europe Neuroendocrine Tumors (NETs) Treatment Sales Price by Type (2021-2026) & (US$/unit) Table 126. Europe Neuroendocrine Tumors (NETs) Treatment Sales Price by Type (2027-2032) & (US$/unit) Table 127. Europe Neuroendocrine Tumors (NETs) Treatment Revenue by Application (2021-2026) & (US$ Million) Table 128. Europe Neuroendocrine Tumors (NETs) Treatment Revenue by Application (2027-2032) & (US$ Million) Table 129. Europe Neuroendocrine Tumors (NETs) Treatment Sales by Application (2021-2026) & (k units) Table 130. Europe Neuroendocrine Tumors (NETs) Treatment Sales by Application (2027-2032) & (k units) Table 131. Europe Neuroendocrine Tumors (NETs) Treatment Sales Price by Application (2021-2026) & (US$/unit) Table 132. Europe Neuroendocrine Tumors (NETs) Treatment Sales Price by Application (2027-2032) & (US$/unit) Table 133. Europe Neuroendocrine Tumors (NETs) Treatment Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 134. Europe Neuroendocrine Tumors (NETs) Treatment Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 135. Europe Neuroendocrine Tumors (NETs) Treatment Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 136. Europe Neuroendocrine Tumors (NETs) Treatment Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 137. Europe Neuroendocrine Tumors (NETs) Treatment Sales by Country (2021-2026) & (k units) Table 138. Europe Neuroendocrine Tumors (NETs) Treatment Sales by Country (2027-2032) & (k units) Table 139. Europe Neuroendocrine Tumors (NETs) Treatment Sales Price by Country (2021-2026) & (US$/unit) Table 140. Europe Neuroendocrine Tumors (NETs) Treatment Sales Price by Country (2027-2032) & (US$/unit) Table 141. Germany Neuroendocrine Tumors (NETs) Treatment Revenue (2021-2032) & (US$ Million) Table 142. France Neuroendocrine Tumors (NETs) Treatment Revenue (2021-2032) & (US$ Million) Table 143. U.K. Neuroendocrine Tumors (NETs) Treatment Revenue (2021-2032) & (US$ Million) Table 144. Italy Neuroendocrine Tumors (NETs) Treatment Revenue (2021-2032) & (US$ Million) Table 145. Russia Neuroendocrine Tumors (NETs) Treatment Revenue (2021-2032) & (US$ Million) Table 146. Spain Neuroendocrine Tumors (NETs) Treatment Revenue (2021-2032) & (US$ Million) Table 147. Netherlands Neuroendocrine Tumors (NETs) Treatment Revenue (2021-2032) & (US$ Million) Table 148. Switzerland Neuroendocrine Tumors (NETs) Treatment Revenue (2021-2032) & (US$ Million) Table 149. Sweden Neuroendocrine Tumors (NETs) Treatment Revenue (2021-2032) & (US$ Million) Table 150. Poland Neuroendocrine Tumors (NETs) Treatment Revenue (2021-2032) & (US$ Million) Table 151. China Neuroendocrine Tumors (NETs) Treatment Revenue by Type (2021-2026) & (US$ Million) Table 152. China Neuroendocrine Tumors (NETs) Treatment Revenue by Type (2027-2032) & (US$ Million) Table 153. China Neuroendocrine Tumors (NETs) Treatment Sales by Type (2021-2026) & (k units) Table 154. China Neuroendocrine Tumors (NETs) Treatment Sales by Type (2027-2032) & (k units) Table 155. China Neuroendocrine Tumors (NETs) Treatment Sales Price by Type (2021-2026) & (US$/unit) Table 156. China Neuroendocrine Tumors (NETs) Treatment Sales Price by Type (2027-2032) & (US$/unit) Table 157. China Neuroendocrine Tumors (NETs) Treatment Revenue by Application (2021-2026) & (US$ Million) Table 158. China Neuroendocrine Tumors (NETs) Treatment Revenue by Application (2027-2032) & (US$ Million) Table 159. China Neuroendocrine Tumors (NETs) Treatment Sales by Application (2021-2026) & (k units) Table 160. China Neuroendocrine Tumors (NETs) Treatment Sales by Application (2027-2032) & (k units) Table 161. China Neuroendocrine Tumors (NETs) Treatment Sales Price by Application (2021-2026) & (US$/unit) Table 162. China Neuroendocrine Tumors (NETs) Treatment Sales Price by Application (2027-2032) & (US$/unit) Table 163. Asia Neuroendocrine Tumors (NETs) Treatment Revenue by Type (2021-2026) & (US$ Million) Table 164. Asia Neuroendocrine Tumors (NETs) Treatment Revenue by Type (2027-2032) & (US$ Million) Table 165. Asia Neuroendocrine Tumors (NETs) Treatment Sales by Type (2021-2026) & (k units) Table 166. Asia Neuroendocrine Tumors (NETs) Treatment Sales by Type (2027-2032) & (k units) Table 167. Asia Neuroendocrine Tumors (NETs) Treatment Sales Price by Type (2021-2026) & (US$/unit) Table 168. Asia Neuroendocrine Tumors (NETs) Treatment Sales Price by Type (2027-2032) & (US$/unit) Table 169. Asia Neuroendocrine Tumors (NETs) Treatment Revenue by Application (2021-2026) & (US$ Million) Table 170. Asia Neuroendocrine Tumors (NETs) Treatment Revenue by Application (2027-2032) & (US$ Million) Table 171. Asia Neuroendocrine Tumors (NETs) Treatment Sales by Application (2021-2026) & (k units) Table 172. Asia Neuroendocrine Tumors (NETs) Treatment Sales by Application (2027-2032) & (k units) Table 173. Asia Neuroendocrine Tumors (NETs) Treatment Sales Price by Application (2021-2026) & (US$/unit) Table 174. Asia Neuroendocrine Tumors (NETs) Treatment Sales Price by Application (2027-2032) & (US$/unit) Table 175. Asia Neuroendocrine Tumors (NETs) Treatment Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 176. Asia Neuroendocrine Tumors (NETs) Treatment Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 177. Asia Neuroendocrine Tumors (NETs) Treatment Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 178. Asia Neuroendocrine Tumors (NETs) Treatment Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 179. Asia Neuroendocrine Tumors (NETs) Treatment Sales by Country (2021-2026) & (k units) Table 180. Asia Neuroendocrine Tumors (NETs) Treatment Sales by Country (2027-2032) & (k units) Table 181. Asia Neuroendocrine Tumors (NETs) Treatment Sales Price by Country (2021-2026) & (US$/unit) Table 182. Asia Neuroendocrine Tumors (NETs) Treatment Sales Price by Country (2027-2032) & (US$/unit) Table 183. Japan Neuroendocrine Tumors (NETs) Treatment Revenue (2021-2032) & (US$ Million) Table 184. South Korea Neuroendocrine Tumors (NETs) Treatment Revenue (2021-2032) & (US$ Million) Table 185. India Neuroendocrine Tumors (NETs) Treatment Revenue (2021-2032) & (US$ Million) Table 186. Australia Neuroendocrine Tumors (NETs) Treatment Revenue (2021-2032) & (US$ Million) Table 187. Taiwan Neuroendocrine Tumors (NETs) Treatment Revenue (2021-2032) & (US$ Million) Table 188. Southeast Asia Neuroendocrine Tumors (NETs) Treatment Revenue (2021-2032) & (US$ Million) Table 189. SAMEA Neuroendocrine Tumors (NETs) Treatment Revenue by Type (2021-2026) & (US$ Million) Table 190. SAMEA Neuroendocrine Tumors (NETs) Treatment Revenue by Type (2027-2032) & (US$ Million) Table 191. SAMEA Neuroendocrine Tumors (NETs) Treatment Sales by Type (2021-2026) & (k units) Table 192. SAMEA Neuroendocrine Tumors (NETs) Treatment Sales by Type (2027-2032) & (k units) Table 193. SAMEA Neuroendocrine Tumors (NETs) Treatment Sales Price by Type (2021-2026) & (US$/unit) Table 194. SAMEA Neuroendocrine Tumors (NETs) Treatment Sales Price by Type (2027-2032) & (US$/unit) Table 195. SAMEA Neuroendocrine Tumors (NETs) Treatment Revenue by Application (2021-2026) & (US$ Million) Table 196. SAMEA Neuroendocrine Tumors (NETs) Treatment Revenue by Application (2027-2032) & (US$ Million) Table 197. SAMEA Neuroendocrine Tumors (NETs) Treatment Sales by Application (2021-2026) & (k units) Table 198. SAMEA Neuroendocrine Tumors (NETs) Treatment Sales by Application (2027-2032) & (k units) Table 199. SAMEA Neuroendocrine Tumors (NETs) Treatment Sales Price by Application (2021-2026) & (US$/unit) Table 200. SAMEA Neuroendocrine Tumors (NETs) Treatment Sales Price by Application (2027-2032) & (US$/unit) Table 201. SAMEA Neuroendocrine Tumors (NETs) Treatment Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 202. SAMEA Neuroendocrine Tumors (NETs) Treatment Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 203. SAMEA Neuroendocrine Tumors (NETs) Treatment Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 204. SAMEA Neuroendocrine Tumors (NETs) Treatment Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 205. SAMEA Neuroendocrine Tumors (NETs) Treatment Sales by Country (2021-2026) & (k units) Table 206. SAMEA Neuroendocrine Tumors (NETs) Treatment Sales by Country (2027-2032) & (k units) Table 207. SAMEA Neuroendocrine Tumors (NETs) Treatment Sales Price by Country (2021-2026) & (US$/unit) Table 208. SAMEA Neuroendocrine Tumors (NETs) Treatment Sales Price by Country (2027-2032) & (US$/unit) Table 209. Brazil Neuroendocrine Tumors (NETs) Treatment Revenue (2021-2032) & (US$ Million) Table 210. Argentina Neuroendocrine Tumors (NETs) Treatment Revenue (2021-2032) & (US$ Million) Table 211. Chile Neuroendocrine Tumors (NETs) Treatment Revenue (2021-2032) & (US$ Million) Table 212. Colombia Neuroendocrine Tumors (NETs) Treatment Revenue (2021-2032) & (US$ Million) Table 213. Peru Neuroendocrine Tumors (NETs) Treatment Revenue (2021-2032) & (US$ Million) Table 214. Saudi Arabia Neuroendocrine Tumors (NETs) Treatment Revenue (2021-2032) & (US$ Million) Table 215. Israel Neuroendocrine Tumors (NETs) Treatment Revenue (2021-2032) & (US$ Million) Table 216. UAE Neuroendocrine Tumors (NETs) Treatment Revenue (2021-2032) & (US$ Million) Table 217. Turkey Neuroendocrine Tumors (NETs) Treatment Revenue (2021-2032) & (US$ Million) Table 218. Iran Neuroendocrine Tumors (NETs) Treatment Revenue (2021-2032) & (US$ Million) Table 219. Egypt Neuroendocrine Tumors (NETs) Treatment Revenue (2021-2032) & (US$ Million) Table 220. Key Raw Materials Table 221. Raw Materials Key Suppliers Table 222. Neuroendocrine Tumors (NETs) Treatment Distributors List Table 223. Neuroendocrine Tumors (NETs) Treatment Customers List Table 224. Research Programs/Design for This Report Table 225. Authors List of This Report Table 226. Secondary Sources Table 227. Primary Sources List of Figures Figure 1. Neuroendocrine Tumors (NETs) Treatment Image Figure 2. Global Neuroendocrine Tumors (NETs) Treatment Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Neuroendocrine Tumors (NETs) Treatment Market Size Share 2021 VS 2025 VS 2032 Figure 4. Somatostatin Analogs (SSAs) Image Figure 5. Targeted Therapy Image Figure 6. Other Image Figure 7. Global Neuroendocrine Tumors (NETs) Treatment Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Neuroendocrine Tumors (NETs) Treatment Market Size Share 2021 VS 2025 VS 2032 Figure 9. Hospitals Image Figure 10. Clinics Image Figure 11. Other Image Figure 12. Global Neuroendocrine Tumors (NETs) Treatment Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Neuroendocrine Tumors (NETs) Treatment Revenue (2021-2032) & (US$ Million) Figure 14. Global Neuroendocrine Tumors (NETs) Treatment Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 15. Global Neuroendocrine Tumors (NETs) Treatment Revenue Market Share by Region: 2025 Versus 2032 Figure 16. Global Neuroendocrine Tumors (NETs) Treatment Revenue Market Share by Region (2021-2032) Figure 17. Global Neuroendocrine Tumors (NETs) Treatment Sales (2021-2032) & (k units) Figure 18. Global Neuroendocrine Tumors (NETs) Treatment Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 19. Global Neuroendocrine Tumors (NETs) Treatment Sales Market Share by Region (2021-2032) Figure 20. US & Canada & Mexico Neuroendocrine Tumors (NETs) Treatment Sales YoY (2021-2032) & (k units) Figure 21. Europe Neuroendocrine Tumors (NETs) Treatment Sales YoY (2021-2032) & (k units) Figure 22. China Neuroendocrine Tumors (NETs) Treatment Sales YoY (2021-2032) & (k units) Figure 23. Asia (Excluding China) Neuroendocrine Tumors (NETs) Treatment Sales YoY (2021-2032) & (k units) Figure 24. South America, Middle East and Africa Neuroendocrine Tumors (NETs) Treatment Sales YoY (2021-2032) & (k units) Figure 25. Global Neuroendocrine Tumors (NETs) Treatment Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 26. Global Neuroendocrine Tumors (NETs) Treatment Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 27. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 28. Global Neuroendocrine Tumors (NETs) Treatment Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 29. Global Neuroendocrine Tumors (NETs) Treatment Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 30. Global Neuroendocrine Tumors (NETs) Treatment Revenue Market Share by Type (2021-2032) Figure 31. Global Neuroendocrine Tumors (NETs) Treatment Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 32. Global Neuroendocrine Tumors (NETs) Treatment Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 33. Global Neuroendocrine Tumors (NETs) Treatment Sales Market Share by Type (2021-2032) Figure 34. Global Neuroendocrine Tumors (NETs) Treatment Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 35. Global Neuroendocrine Tumors (NETs) Treatment Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 36. Global Neuroendocrine Tumors (NETs) Treatment Revenue Market Share by Application (2021-2032) Figure 37. Global Neuroendocrine Tumors (NETs) Treatment Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 38. Global Neuroendocrine Tumors (NETs) Treatment Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 39. Global Neuroendocrine Tumors (NETs) Treatment Sales Market Share by Application (2021-2032) Figure 40. North America Neuroendocrine Tumors (NETs) Treatment Revenue Share by Type (2021-2032) Figure 41. North America Neuroendocrine Tumors (NETs) Treatment Sales Share by Type (2021-2032) Figure 42. North America Neuroendocrine Tumors (NETs) Treatment Revenue Share by Application (2021-2032) Figure 43. North America Neuroendocrine Tumors (NETs) Treatment Sales Share by Application (2021-2032) Figure 44. North America Neuroendocrine Tumors (NETs) Treatment Revenue Share by Country (2021-2032) Figure 45. North America Neuroendocrine Tumors (NETs) Treatment Sales Share by Country (2021-2032) Figure 46. Europe Neuroendocrine Tumors (NETs) Treatment Revenue Share by Type (2021-2032) Figure 47. Europe Neuroendocrine Tumors (NETs) Treatment Sales Share by Type (2021-2032) Figure 48. Europe Neuroendocrine Tumors (NETs) Treatment Revenue Share by Application (2021-2032) Figure 49. Europe Neuroendocrine Tumors (NETs) Treatment Sales Share by Application (2021-2032) Figure 50. Europe Neuroendocrine Tumors (NETs) Treatment Revenue Share by Country (2021-2032) Figure 51. Europe Neuroendocrine Tumors (NETs) Treatment Sales Share by Country (2021-2032) Figure 52. China Neuroendocrine Tumors (NETs) Treatment Revenue Share by Type (2021-2032) Figure 53. China Neuroendocrine Tumors (NETs) Treatment Sales Share by Type (2021-2032) Figure 54. China Neuroendocrine Tumors (NETs) Treatment Revenue Share by Application (2021-2032) Figure 55. China Neuroendocrine Tumors (NETs) Treatment Sales Share by Application (2021-2032) Figure 56. Asia Neuroendocrine Tumors (NETs) Treatment Revenue Share by Type (2021-2032) Figure 57. Asia Neuroendocrine Tumors (NETs) Treatment Sales Share by Type (2021-2032) Figure 58. Asia Neuroendocrine Tumors (NETs) Treatment Revenue Share by Application (2021-2032) Figure 59. Asia Neuroendocrine Tumors (NETs) Treatment Sales Share by Application (2021-2032) Figure 60. Asia Neuroendocrine Tumors (NETs) Treatment Revenue Share by Country (2021-2032) Figure 61. Asia Neuroendocrine Tumors (NETs) Treatment Sales Share by Country (2021-2032) Figure 62. SAMEA Neuroendocrine Tumors (NETs) Treatment Revenue Share by Type (2021-2032) Figure 63. SAMEA Neuroendocrine Tumors (NETs) Treatment Sales Share by Type (2021-2032) Figure 64. SAMEA Neuroendocrine Tumors (NETs) Treatment Revenue Share by Application (2021-2032) Figure 65. SAMEA Neuroendocrine Tumors (NETs) Treatment Sales Share by Application (2021-2032) Figure 66. SAMEA Neuroendocrine Tumors (NETs) Treatment Revenue Share by Country (2021-2032) Figure 67. SAMEA Neuroendocrine Tumors (NETs) Treatment Sales Share by Country (2021-2032) Figure 68. Neuroendocrine Tumors (NETs) Treatment Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Neuroendocrine Tumors (NETs) Treatment Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Somatostatin Analogs (SSAs)
  • Targeted Therapy
  • Other
Applications
  • Hospitals
  • Clinics
  • Other
Companies covered
  • Novartis AG
  • Pfizer, Inc
  • Progenics Pharmaceuticals
  • IpsenPharma
  • Hutchison MediPharma Limited
  • Boehringer Ingelheim International
  • AVEO Oncology
  • Advanced Accelerator Applications

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Neuroendocrine Tumors (NETs) Treatment Market by Type
  3. 1.2.1 Global Neuroendocrine Tumors (NETs) Treatment Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Somatostatin Analogs (SSAs)
  5. 1.2.3 Targeted Therapy
  6. 1.2.4 Other
  7. 1.3 Neuroendocrine Tumors (NETs) Treatment Market by Application
  8. 1.3.1 Global Neuroendocrine Tumors (NETs) Treatment Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Hospitals
  10. 1.3.3 Clinics
  11. 1.3.4 Other
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Neuroendocrine Tumors (NETs) Treatment Market Dynamics
  1. 2.1 Neuroendocrine Tumors (NETs) Treatment Industry Trends
  2. 2.2 Neuroendocrine Tumors (NETs) Treatment Industry Drivers
  3. 2.3 Neuroendocrine Tumors (NETs) Treatment Industry Opportunities and Challenges
  4. 2.4 Neuroendocrine Tumors (NETs) Treatment Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Neuroendocrine Tumors (NETs) Treatment Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Neuroendocrine Tumors (NETs) Treatment Revenue by Region
  3. 3.2.1 Global Neuroendocrine Tumors (NETs) Treatment Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Neuroendocrine Tumors (NETs) Treatment Revenue by Region (2021-2026)
  5. 3.2.3 Global Neuroendocrine Tumors (NETs) Treatment Revenue by Region (2027-2032)
  6. 3.2.4 Global Neuroendocrine Tumors (NETs) Treatment Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Neuroendocrine Tumors (NETs) Treatment Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Neuroendocrine Tumors (NETs) Treatment Sales by Region
  9. 3.4.1 Global Neuroendocrine Tumors (NETs) Treatment Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Neuroendocrine Tumors (NETs) Treatment Sales by Region (2021-2026)
  11. 3.4.3 Global Neuroendocrine Tumors (NETs) Treatment Sales by Region (2027-2032)
  12. 3.4.4 Global Neuroendocrine Tumors (NETs) Treatment Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Neuroendocrine Tumors (NETs) Treatment Revenue by Manufacturers
  2. 4.1.1 Global Neuroendocrine Tumors (NETs) Treatment Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Neuroendocrine Tumors (NETs) Treatment Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Neuroendocrine Tumors (NETs) Treatment Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Neuroendocrine Tumors (NETs) Treatment Sales by Manufacturers
  6. 4.2.1 Global Neuroendocrine Tumors (NETs) Treatment Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Neuroendocrine Tumors (NETs) Treatment Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Neuroendocrine Tumors (NETs) Treatment Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Neuroendocrine Tumors (NETs) Treatment Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Neuroendocrine Tumors (NETs) Treatment Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Neuroendocrine Tumors (NETs) Treatment Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Neuroendocrine Tumors (NETs) Treatment Manufacturers, Product Type & Application
  13. 4.7 Global Neuroendocrine Tumors (NETs) Treatment Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Neuroendocrine Tumors (NETs) Treatment Market CR5 and HHI
  16. 4.8.2 2025 Neuroendocrine Tumors (NETs) Treatment Tier 1, Tier 2, and Tier 3
5 Neuroendocrine Tumors (NETs) Treatment Market by Type
  1. 5.1 Global Neuroendocrine Tumors (NETs) Treatment Revenue by Type
  2. 5.1.1 Global Neuroendocrine Tumors (NETs) Treatment Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Neuroendocrine Tumors (NETs) Treatment Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Neuroendocrine Tumors (NETs) Treatment Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Neuroendocrine Tumors (NETs) Treatment Sales by Type
  6. 5.2.1 Global Neuroendocrine Tumors (NETs) Treatment Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Neuroendocrine Tumors (NETs) Treatment Sales by Type (2021-2032) & (k units)
  8. 5.2.3 Global Neuroendocrine Tumors (NETs) Treatment Sales Market Share by Type (2021-2032)
  9. 5.3 Global Neuroendocrine Tumors (NETs) Treatment Price by Type
6 Neuroendocrine Tumors (NETs) Treatment Market by Application
  1. 6.1 Global Neuroendocrine Tumors (NETs) Treatment Revenue by Application
  2. 6.1.1 Global Neuroendocrine Tumors (NETs) Treatment Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Neuroendocrine Tumors (NETs) Treatment Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Neuroendocrine Tumors (NETs) Treatment Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Neuroendocrine Tumors (NETs) Treatment Sales by Application
  6. 6.2.1 Global Neuroendocrine Tumors (NETs) Treatment Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Neuroendocrine Tumors (NETs) Treatment Sales by Application (2021-2032) & (k units)
  8. 6.2.3 Global Neuroendocrine Tumors (NETs) Treatment Sales Market Share by Application (2021-2032)
  9. 6.3 Global Neuroendocrine Tumors (NETs) Treatment Price by Application
7 Company Profiles
  1. 7.1 Novartis AG
  2. 7.1.1 Novartis AG Company Information
  3. 7.1.2 Novartis AG Business Overview
  4. 7.1.3 Novartis AG Neuroendocrine Tumors (NETs) Treatment Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Novartis AG Neuroendocrine Tumors (NETs) Treatment Product Portfolio
  6. 7.1.5 Novartis AG Recent Developments
  7. 7.2 Pfizer, Inc
  8. 7.2.1 Pfizer, Inc Company Information
  9. 7.2.2 Pfizer, Inc Business Overview
  10. 7.2.3 Pfizer, Inc Neuroendocrine Tumors (NETs) Treatment Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Pfizer, Inc Neuroendocrine Tumors (NETs) Treatment Product Portfolio
  12. 7.2.5 Pfizer, Inc Recent Developments
  13. 7.3 Progenics Pharmaceuticals
  14. 7.3.1 Progenics Pharmaceuticals Company Information
  15. 7.3.2 Progenics Pharmaceuticals Business Overview
  16. 7.3.3 Progenics Pharmaceuticals Neuroendocrine Tumors (NETs) Treatment Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Progenics Pharmaceuticals Neuroendocrine Tumors (NETs) Treatment Product Portfolio
  18. 7.3.5 Progenics Pharmaceuticals Recent Developments
  19. 7.4 IpsenPharma
  20. 7.4.1 IpsenPharma Company Information
  21. 7.4.2 IpsenPharma Business Overview
  22. 7.4.3 IpsenPharma Neuroendocrine Tumors (NETs) Treatment Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 IpsenPharma Neuroendocrine Tumors (NETs) Treatment Product Portfolio
  24. 7.4.5 IpsenPharma Recent Developments
  25. 7.5 Hutchison MediPharma Limited
  26. 7.5.1 Hutchison MediPharma Limited Company Information
  27. 7.5.2 Hutchison MediPharma Limited Business Overview
  28. 7.5.3 Hutchison MediPharma Limited Neuroendocrine Tumors (NETs) Treatment Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Hutchison MediPharma Limited Neuroendocrine Tumors (NETs) Treatment Product Portfolio
  30. 7.5.5 Hutchison MediPharma Limited Recent Developments
  31. 7.6 Boehringer Ingelheim International
  32. 7.6.1 Boehringer Ingelheim International Company Information
  33. 7.6.2 Boehringer Ingelheim International Business Overview
  34. 7.6.3 Boehringer Ingelheim International Neuroendocrine Tumors (NETs) Treatment Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Boehringer Ingelheim International Neuroendocrine Tumors (NETs) Treatment Product Portfolio
  36. 7.6.5 Boehringer Ingelheim International Recent Developments
  37. 7.7 AVEO Oncology
  38. 7.7.1 AVEO Oncology Company Information
  39. 7.7.2 AVEO Oncology Business Overview
  40. 7.7.3 AVEO Oncology Neuroendocrine Tumors (NETs) Treatment Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 AVEO Oncology Neuroendocrine Tumors (NETs) Treatment Product Portfolio
  42. 7.7.5 AVEO Oncology Recent Developments
  43. 7.8 Advanced Accelerator Applications
  44. 7.8.1 Advanced Accelerator Applications Company Information
  45. 7.8.2 Advanced Accelerator Applications Business Overview
  46. 7.8.3 Advanced Accelerator Applications Neuroendocrine Tumors (NETs) Treatment Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Advanced Accelerator Applications Neuroendocrine Tumors (NETs) Treatment Product Portfolio
  48. 7.8.5 Advanced Accelerator Applications Recent Developments
8 North America
  1. 8.1 North America Neuroendocrine Tumors (NETs) Treatment Market Size by Type
  2. 8.1.1 North America Neuroendocrine Tumors (NETs) Treatment Revenue by Type (2021-2032)
  3. 8.1.2 North America Neuroendocrine Tumors (NETs) Treatment Sales by Type (2021-2032)
  4. 8.1.3 North America Neuroendocrine Tumors (NETs) Treatment Price by Type (2021-2032)
  5. 8.2 North America Neuroendocrine Tumors (NETs) Treatment Market Size by Application
  6. 8.2.1 North America Neuroendocrine Tumors (NETs) Treatment Revenue by Application (2021-2032)
  7. 8.2.2 North America Neuroendocrine Tumors (NETs) Treatment Sales by Application (2021-2032)
  8. 8.2.3 North America Neuroendocrine Tumors (NETs) Treatment Price by Application (2021-2032)
  9. 8.3 North America Neuroendocrine Tumors (NETs) Treatment Market Size by Country
  10. 8.3.1 North America Neuroendocrine Tumors (NETs) Treatment Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Neuroendocrine Tumors (NETs) Treatment Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Neuroendocrine Tumors (NETs) Treatment Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Neuroendocrine Tumors (NETs) Treatment Market Size by Type
  2. 9.1.1 Europe Neuroendocrine Tumors (NETs) Treatment Revenue by Type (2021-2032)
  3. 9.1.2 Europe Neuroendocrine Tumors (NETs) Treatment Sales by Type (2021-2032)
  4. 9.1.3 Europe Neuroendocrine Tumors (NETs) Treatment Price by Type (2021-2032)
  5. 9.2 Europe Neuroendocrine Tumors (NETs) Treatment Market Size by Application
  6. 9.2.1 Europe Neuroendocrine Tumors (NETs) Treatment Revenue by Application (2021-2032)
  7. 9.2.2 Europe Neuroendocrine Tumors (NETs) Treatment Sales by Application (2021-2032)
  8. 9.2.3 Europe Neuroendocrine Tumors (NETs) Treatment Price by Application (2021-2032)
  9. 9.3 Europe Neuroendocrine Tumors (NETs) Treatment Market Size by Country
  10. 9.3.1 Europe Neuroendocrine Tumors (NETs) Treatment Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Neuroendocrine Tumors (NETs) Treatment Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Neuroendocrine Tumors (NETs) Treatment Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Neuroendocrine Tumors (NETs) Treatment Market Size by Type
  2. 10.1.1 China Neuroendocrine Tumors (NETs) Treatment Revenue by Type (2021-2032)
  3. 10.1.2 China Neuroendocrine Tumors (NETs) Treatment Sales by Type (2021-2032)
  4. 10.1.3 China Neuroendocrine Tumors (NETs) Treatment Price by Type (2021-2032)
  5. 10.2 China Neuroendocrine Tumors (NETs) Treatment Market Size by Application
  6. 10.2.1 China Neuroendocrine Tumors (NETs) Treatment Revenue by Application (2021-2032)
  7. 10.2.2 China Neuroendocrine Tumors (NETs) Treatment Sales by Application (2021-2032)
  8. 10.2.3 China Neuroendocrine Tumors (NETs) Treatment Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Neuroendocrine Tumors (NETs) Treatment Market Size by Type
  2. 11.1.1 Asia Neuroendocrine Tumors (NETs) Treatment Revenue by Type (2021-2032)
  3. 11.1.2 Asia Neuroendocrine Tumors (NETs) Treatment Sales by Type (2021-2032)
  4. 11.1.3 Asia Neuroendocrine Tumors (NETs) Treatment Price by Type (2021-2032)
  5. 11.2 Asia Neuroendocrine Tumors (NETs) Treatment Market Size by Application
  6. 11.2.1 Asia Neuroendocrine Tumors (NETs) Treatment Revenue by Application (2021-2032)
  7. 11.2.2 Asia Neuroendocrine Tumors (NETs) Treatment Sales by Application (2021-2032)
  8. 11.2.3 Asia Neuroendocrine Tumors (NETs) Treatment Price by Application (2021-2032)
  9. 11.3 Asia Neuroendocrine Tumors (NETs) Treatment Market Size by Country
  10. 11.3.1 Asia Neuroendocrine Tumors (NETs) Treatment Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Neuroendocrine Tumors (NETs) Treatment Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Neuroendocrine Tumors (NETs) Treatment Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Neuroendocrine Tumors (NETs) Treatment Market Size by Type
  2. 12.1.1 SAMEA Neuroendocrine Tumors (NETs) Treatment Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Neuroendocrine Tumors (NETs) Treatment Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Neuroendocrine Tumors (NETs) Treatment Price by Type (2021-2032)
  5. 12.2 SAMEA Neuroendocrine Tumors (NETs) Treatment Market Size by Application
  6. 12.2.1 SAMEA Neuroendocrine Tumors (NETs) Treatment Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Neuroendocrine Tumors (NETs) Treatment Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Neuroendocrine Tumors (NETs) Treatment Price by Application (2021-2032)
  9. 12.3 SAMEA Neuroendocrine Tumors (NETs) Treatment Market Size by Country
  10. 12.3.1 SAMEA Neuroendocrine Tumors (NETs) Treatment Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Neuroendocrine Tumors (NETs) Treatment Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Neuroendocrine Tumors (NETs) Treatment Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Neuroendocrine Tumors (NETs) Treatment Value Chain Analysis
  2. 13.1.1 Neuroendocrine Tumors (NETs) Treatment Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Neuroendocrine Tumors (NETs) Treatment Production Mode & Process
  6. 13.2 Neuroendocrine Tumors (NETs) Treatment Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Neuroendocrine Tumors (NETs) Treatment Distributors
  9. 13.2.3 Neuroendocrine Tumors (NETs) Treatment Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst